200 related articles for article (PubMed ID: 14743567)
1. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
2. Results of postchemotherapy adjunctive retroperitoneal lymph node dissection in non-seminomatous germ cell cancer patients.
Goepel M; Recker F; Otto T; Krege S; Rübben H
Urol Int; 1996; 57(4):209-12. PubMed ID: 8961487
[TBL] [Abstract][Full Text] [Related]
3. Laparoscopic retroperitoneal lymphadenectomy for stage I non-seminomatous testicular tumors.
Custureri F; Urciuoli P; Iavarone C; D'Orazi V; Gabatel R; Ghinassi S; Patrizi G; Palazzini G; Di Matteo FM; Peparini N
Hepatogastroenterology; 2005; 52(66):1677-80. PubMed ID: 16334755
[TBL] [Abstract][Full Text] [Related]
4. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors.
Aprikian AG; Herr HW; Bajorin DF; Bosl GJ
Cancer; 1994 Aug; 74(4):1329-34. PubMed ID: 8055456
[TBL] [Abstract][Full Text] [Related]
5. Post-chemotherapy residual mass in non-seminomatous testicular cancer. The role of retroperitoneal lymph node dissection.
El Sayed S; Grando JP; Almeida SH; Mortati Neto N; Moreira HA
Int Braz J Urol; 2004; 30(5):384-8. PubMed ID: 15610570
[TBL] [Abstract][Full Text] [Related]
6. Repeat retroperitoneal lymphadenectomy in advanced testicular cancer.
Heidenreich A; Ohlmann C; Hegele A; Beyer J
Eur Urol; 2005 Jan; 47(1):64-71. PubMed ID: 15582251
[TBL] [Abstract][Full Text] [Related]
7. Survival of patients with viable malignant non-seminomatous germ cell tumour persistent after cisplatin-based induction chemotherapy.
Hollender A; Stenwig EA; Ous S; Fosså SD
Eur Urol; 1997; 31(2):141-7. PubMed ID: 9076455
[TBL] [Abstract][Full Text] [Related]
8. Delayed orchiectomy after chemotherapy in patients with advanced testicular cancer.
Ondrus D; Hornák M; Breza J; Mat'oska J; Schnorrer M; Belan V; Kausitz J
Int Urol Nephrol; 2001; 32(4):665-7. PubMed ID: 11989561
[TBL] [Abstract][Full Text] [Related]
9. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors.
Spermon JR; Roeleveld TA; van der Poel HG; Hulsbergen-van de Kaa CA; Ten Bokkel Huinink WW; van de Vijver M; Witjes JA; Horenblas S
Urology; 2002 Jun; 59(6):923-9. PubMed ID: 12031382
[TBL] [Abstract][Full Text] [Related]
10. Is modified retroperitoneal lymph node dissection (MRLND) still feasible in the treatment of patients with clinical stage I non-seminomatous testicular cancer?
Sosnowski M; Jeromin L; Płuzańska A
Int Urol Nephrol; 1994; 26(4):471-7. PubMed ID: 7528180
[TBL] [Abstract][Full Text] [Related]
11. Comparison of histological results from the resection of residual masses at different sites after chemotherapy for metastatic non-seminomatous germ cell tumours.
Hartmann JT; Candelaria M; Kuczyk MA; Schmoll HJ; Bokemeyer C
Eur J Cancer; 1997 May; 33(6):843-7. PubMed ID: 9291803
[TBL] [Abstract][Full Text] [Related]
12. Improved management of abdominal undescended testicular tumors with bulky confluent retroperitoneal nodal metastases.
Kulkarni JN; Desai SM; Phadke GK; Tongaonkar HB
J Urol; 1996 Oct; 156(4):1341-4. PubMed ID: 8808867
[TBL] [Abstract][Full Text] [Related]
13. Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.
Motzer RJ; Sheinfeld J; Mazumdar M; Bajorin DF; Bosl GJ; Herr H; Lyn P; Vlamis V
J Clin Oncol; 1995 Nov; 13(11):2700-4. PubMed ID: 7595727
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancer. the Indiana University experience.
Behnia M; Foster R; Einhorn LH; Donohue J; Nichols CR
Eur J Cancer; 2000 Mar; 36(4):472-5. PubMed ID: 10717522
[TBL] [Abstract][Full Text] [Related]
15. Reoperative retroperitoneal surgery for nonseminomatous germ cell tumor: clinical presentation, patterns of recurrence, and outcome.
McKiernan JM; Motzer RJ; Bajorin DF; Bacik J; Bosl GJ; Sheinfeld J
Urology; 2003 Oct; 62(4):732-6. PubMed ID: 14550453
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome of retroperitoneal lymph node dissection after induction chemotherapy for metastatic non-seminomatous germ cell tumors.
Muramaki M; Hara I; Miyake H; Yamada Y; Okada H; Kamidono S
Int J Urol; 2004 Sep; 11(9):763-7. PubMed ID: 15379941
[TBL] [Abstract][Full Text] [Related]
17. Clinical stage B non-seminomatous germ cell testis cancer: the Indiana University experience (1965-1989) using routine primary retroperitoneal lymph node dissection.
Donohue JP; Thornhill JA; Foster RS; Rowland RG; Bihrle R
Eur J Cancer; 1995 Sep; 31A(10):1599-604. PubMed ID: 7488408
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of clinical staging in non-seminomatous testicular cancer--a single centre experience of retroperitoneal lymph node dissection.
Carlsson-Farrelly E; Boquist L; Ljungberg B
Scand J Urol Nephrol; 1995 Dec; 29(4):501-6. PubMed ID: 8719370
[TBL] [Abstract][Full Text] [Related]
19. [Urologic treatment of testicular germ cell cancer].
Fernández Gómez JM; Escaf Barmadah S; Guate Ortiz JL; Martín Huescar A; Fresno Forcelledo F; García Rodríguez J; Rodríguez Faba O; Jalón Monzón A; Rodríguez Martínez JJ
Arch Esp Urol; 2002 Oct; 55(8):927-36. PubMed ID: 12455283
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of primary standard cisplatin-based chemotherapy for clinical stage II non-seminomatous germ cell tumours of the testis.
Culine S; Theodore C; Court BH; Perrin JL; Droz JP
Br J Urol; 1997 Feb; 79(2):258-62. PubMed ID: 9052479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
